Penin­su­la is a bio­phar­ma­ceu­ti­cal com­pa­ny focused on the devel­op­ment and com­mer­cial­iza­tion of antibi­otics to treat life-threat­en­ing infec­tions. The Company’s mis­sion is to devel­op opti­mal anti-infec­tive ther­a­pies that offer improved effi­ca­cy, dos­ing and safe­ty char­ac­ter­is­tics over exist­ing ther­a­pies. In addi­tion to DBL Part­ners, investors include Canaan Part­ners and Domain Associates.

Penin­su­la was acquired by John­son & John­son on June 30th, 2005.